Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial

VS Chachay, Jennifer H Martin, JB Prins, JP Whitehead, Trisha M O'Moore-Sullivan, Paul Lee, M Franklin, K Klein, PJ Taylor, Maree Ferguson, JS Coombes, Gethin Thomas, Gary J Cowin, C. Kirkpatrick, graeme MacDonald, Ingrid Hickman

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.
    Original languageEnglish
    Pages (from-to)78-79
    Number of pages2
    JournalJournal of Gastroenterology and Hepatology (Australia)
    Volume28
    Issue numberSupplement 2
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Chachay, VS., Martin, J. H., Prins, JB., Whitehead, JP., O'Moore-Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, PJ., Ferguson, M., Coombes, JS., Thomas, G., Cowin, G. J., Kirkpatrick, C., MacDonald, G., & Hickman, I. (2013). Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial. Journal of Gastroenterology and Hepatology (Australia), 28(Supplement 2), 78-79.